Bellicum reports OS rates from Phase I/II of adjunct T cell therapy BPX-501

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) reported data from 38 pediatric patients with acute myelogenous leukemia (AML) and 59 patients with primary immunodeficiencies undergoing a haploidentical hematopoietic stem cell transplant

Read the full 286 word article

User Sign In